Page last updated: 2024-12-06

lumiflavin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Lumiflavin is a derivative of riboflavin (vitamin B2) and is produced by photodegradation of riboflavin. It is a yellow fluorescent compound that absorbs light maximally at 370 nm and emits fluorescence maximally at 510 nm. Lumiflavin is not known to have any biological activity, but it has been used as a model compound to study the photochemistry of riboflavin and other flavins. Lumiflavin is also used as a fluorescent probe in analytical chemistry.'

lumiflavin : A compound showing yellow-green fluorescence, formed by a photolysis of riboflavin in alkaline solution. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID66184
CHEMBL ID1233985
CHEBI ID43661
SCHEMBL ID193713
MeSH IDM0042327

Synonyms (41)

Synonym
CHEMBL1233985
einecs 214-125-5
ccris 6316
benzo(g)pteridine-2,4,(3h,10h)-dione, 7,8,10-trimethyl-
7,8,10-trimethylbenzo(g)pteridine-2,4,(3h,10h)-dione
benzo[g]pteridine-2,4(3h,10h)-dione, 7,8,10-trimethyl-
lumiflavine
lumiflavin
7,8,10-trimethylbenzo[g]pteridine-2,4(3h,10h)-dione
lumilactoflavin
1088-56-8
CHEBI:43661 ,
7,8,10-trimethylisoalloxazine
DB04726
7,8,10-trimethylbenzo(g)pteridine-2,4(3h,10h)-dione
inchi=1/c13h12n4o2/c1-6-4-8-9(5-7(6)2)17(3)11-10(14-8)12(18)16-13(19)15-11/h4-5h,1-3h3,(h,16,18,19)
kpdqzgkjtjrbgu-uhfffaoysa-
7,8,10-trimethylbenzo[g]pteridine-2,4-dione
AKOS004910107
bdbm50362897
unii-4m2669414m
4m2669414m ,
FT-0670872
SCHEMBL193713
lumiflavine [usp impurity]
benzo(g)pteridine-2,4(3h,10h)-dione, 7,8,10-trimethyl-
benzo(g)pteridin-2(10h)-one, 4-hydroxy-7,8,10-trimethyl-
lumiflavine [mi]
riboflavin impurity a [ep impurity]
riboflavin sodium phosphate impurity e [ep impurity]
lumiflavin (iii)
KPDQZGKJTJRBGU-UHFFFAOYSA-N
7,8,10-trimethylbenzo[g]pteridine-2,4(3h,10h)-dione #
mfcd00042742
DTXSID10148745
J-002198
'7,8,10-trimethylbenzo[g]pteridine-2,4(3h,10h)-dione'
Q6703239
AS-82190
HY-121608
7,8,10-trimethyl-2h,3h,4h,10h-benzo[g]pteridine-2,4-dione

Research Excerpts

Actions

ExcerptReferenceRelevance
"Lumiflavin can enhance the effects of ionising radiation on ovarian cancer CSCs. "( Lumiflavin Enhances the Effects of Ionising Radiation on Ovarian Cancer Stem-Like Cells by Inhibiting Autophagy.
Huang, Y; Song, Z; Wu, M; Yang, R, 2021
)
3.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
flavinA derivative of the dimethylisoalloxazine (7,8-dimethylbenzo[g]pteridine-2,4(3H,10H)-dione) skeleton, with a substituent on the 10 position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Riboflavin-binding proteinGallus gallus (chicken)Kd0.06100.00500.35952.1000AID642884
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (3)

Processvia Protein(s)Taxonomy
riboflavin transportRiboflavin-binding proteinGallus gallus (chicken)
negative regulation of sensory perception of sweet tasteRiboflavin-binding proteinGallus gallus (chicken)
negative regulation of sensory perception of bitter tasteRiboflavin-binding proteinGallus gallus (chicken)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
riboflavin transmembrane transporter activityRiboflavin-binding proteinGallus gallus (chicken)
riboflavin bindingRiboflavin-binding proteinGallus gallus (chicken)
signaling receptor activityRiboflavin-binding proteinGallus gallus (chicken)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
external side of plasma membraneRiboflavin-binding proteinGallus gallus (chicken)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID642884Binding affinity to chicken riboflavin binding protein assessed as dissociation constant at pH 7.4 in phosphate buffer by isothermal titration calorimetric assay2011ACS medicinal chemistry letters, May-12, Volume: 2, Issue:5
Bioanalytical Screening of Riboflavin Antagonists for Targeted Drug Delivery - A Thermodynamic and Kinetic Study.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (91)

TimeframeStudies, This Drug (%)All Drugs %
pre-199029 (31.87)18.7374
1990's14 (15.38)18.2507
2000's20 (21.98)29.6817
2010's26 (28.57)24.3611
2020's2 (2.20)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.04 (24.57)
Research Supply Index4.54 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index42.09 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other93 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]